EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Basiliximab vs. No Induction Therapy in Kidney Transplant Recipients with a Low Immunological Risk Profile Receiving Tacrolimus/Mycophenolate/Steroids Maintenance Immunosuppression

Florian Lacave iD, Christophe de Terwangne, Tom Darius iD, Antoine Buemi, Michel Mourad, Yannick France, Joana Cardoso Coelho, Guillaume Fernandes iD, Eric Goffin, Arnaud Devresse, Nada Kanaan

Journal of Clinical Medicine · 16.10.2024 · 13 (20) · 6151

DOI: 10.3390/jcm13206151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.10.2024. Verfasst von Florian Lacave und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Brussels, Belgium. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Induction therapy with basiliximab is recommended in kidney transplant (KT) recipients with a low immunological risk (LIR) profile. Whether basiliximab is associated with a decreased risk of acute rejection (AR) and graft loss is controversial.

Methods

In our institution, LIR patients (absence of anti-HLA antibodies before KT) are inducted with basiliximab in case of living-donor KT, while deceased-donor KT recipients receive no induction. Maintenance immunosuppression is similar, including a combination of tacrolimus (Tac), mycophenolate (MPA) and steroids. In this single-center retrospective study, we included all adult LIR patients who underwent KT between 1 January 2015 and 31 December 2022.

Results

Of the 471 patients included, 354 received no induction and 117 received basiliximab. The median (IQR) number of HLA A-B-DR mismatches was 3 (2–3) and 2 (2–4) in the no induction group and the basiliximab group, respectively. The cumulative incidences in the no induction group vs. the basiliximab group of acute rejection and graft loss over 5 years post-KT were similar at 8.9% vs. 7.8% (p = 0.8) and 8.5% vs. 4.2% (p = 0.063), respectively. In multivariable Cox regression analysis, delayed graft function emerged as an independent risk factor for acute rejection (hazard ratio [HR] 2.75, 95% confidence interval [CI] 1.23–6.13, p = 0.014) and graft loss (HR 9.32, CI 4.10–21.1, p < 0.001).

Conclusions

Basiliximab did not provide any advantage in terms of rate of acute rejection and graft survival within 5 years post KT compared with a strategy without induction therapy in patients with a low immunological risk profile receiving triple maintenance immunosuppression Tac/MPA/steroids.

Schlagwörter

Stichwörter der Autor:innen

acute rejectiongraft lossinductionkidney transplantation

Autor:innen und Institutionen

  • Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Brussels, Belgium.
  • Geriatrics Medecine, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Brussels, Belgium.
  • Institut de Recherche Experimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Brussels, Belgium.
  • Surgery and Abdominal Transplant Unit, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Brussels, Belgium.

ORCID-Profile: Florian Lacave, Tom Darius, Guillaume Fernandes

Zitieren

APA

Lacave, F., de Terwangne, C., Darius, T., Buemi, A., Mourad, M., France, Y., Cardoso Coelho, J., Fernandes, G., Goffin, E., Devresse, A., & Kanaan, N. (2024). Basiliximab vs. No Induction Therapy in Kidney Transplant Recipients with a Low Immunological Risk Profile Receiving Tacrolimus/Mycophenolate/Steroids Maintenance Immunosuppression. Journal of Clinical Medicine, 13(20), 6151. https://doi.org/10.3390/jcm13206151

Vancouver

Lacave F, de Terwangne C, Darius T, Buemi A, Mourad M, France Y, et al. Basiliximab vs. No Induction Therapy in Kidney Transplant Recipients with a Low Immunological Risk Profile Receiving Tacrolimus/Mycophenolate/Steroids Maintenance Immunosuppression. Journal of Clinical Medicine. 2024;13(20):6151. doi:10.3390/jcm13206151

BibTeX
@article{Lacave2024,
  author = {Lacave, Florian and de Terwangne, Christophe and Darius, Tom and Buemi, Antoine and Mourad, Michel and France, Yannick and Cardoso Coelho, Joana and Fernandes, Guillaume and Goffin, Eric and Devresse, Arnaud and Kanaan, Nada},
  title = {Basiliximab vs. No Induction Therapy in Kidney Transplant Recipients with a Low Immunological Risk Profile Receiving Tacrolimus/Mycophenolate/Steroids Maintenance Immunosuppression},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {20},
  pages = {6151},
  doi = {10.3390/jcm13206151}
}
Kostenlos starten →